2.
The march toward malaria vaccines
by Hoffman, Stephen L
Vaccine, 2015, Vol.33 (Suppl 4), p.D13-D23
3.
Development of vaccines for Plasmodium vivax malaria
by Mueller, Ivo
Vaccine, 2015, Vol.33 (52), p.7489-7495
4.
The changing epidemiology of malaria elimination: new strategies for new challenges
by Cotter, Chris, MPH
The Lancet (British edition), 2013, Vol.382 (9895), p.900-911
5.
Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial
by White, Michael T, Dr
The Lancet infectious diseases, 2015, Vol.15 (12), p.1450-1458
6.
Transmission blocking malaria vaccines: Assays and candidates in clinical development
by Sauerwein, R.W
Vaccine, 2015, Vol.33 (52), p.7476-7482
7.
Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models
by Penny, Melissa A, Dr
The Lancet (British edition), 2016, Vol.387 (10016), p.367-375
8.
Burden, pathology, and costs of malaria in pregnancy: new developments for an old problem
by Rogerson, Stephen J
The Lancet infectious diseases, 2018-04, Vol.18 (4), p.e107-e118
9.
Malaria in pregnancy in the Asia-Pacific region
by Rijken, Marcus J, Dr
The Lancet infectious diseases, 2012, Vol.12 (1), p.75-88
10.
Could the RTS,S/AS01 meningitis safety signal really be a protective effect of rabies vaccine?
by Gessner, Bradford D
Vaccine, 2017, Vol.35 (5), p.716-721
11.
Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria
by Schofield, Louis
Nature (London), 2002-08-15, Vol.418 (6899), p.785-789
12.
Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax mal...
by Llanos-Cuentas, Alejandro
The Lancet infectious diseases, 2018-08, Vol.18 (8), p.874-883
13.
Development of vaccines to prevent malaria in pregnant women: WHO MALVAC meeting report
by Menéndez, Clara
Expert review of vaccines, 2011-09-01, Vol.10 (9), p.1271-1280
14.
Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial
by Gomes, MF, Dr
The Lancet (British edition), 2009, Vol.373 (9663), p.557-566
15.
RTS,S: Toward a first landmark on the Malaria Vaccine Technology Roadmap
by Kaslow, David C
Vaccine, 2015, Vol.33 (52), p.7425-7432
16.
Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalatio...
by Sagara, Issaka
The Lancet infectious diseases, 2018-09, Vol.18 (9), p.969-982
17.
Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs
by Murugan, Rajagopal
Nature medicine, 2020-07, Vol.26 (7), p.1135-1145
18.
Immunopathogenesis of falciparum malaria: implications for adjunctive therapy in the management of severe and cerebral malaria
by Higgins, Sarah J
Expert review of anti-infective therapy, 2011-09-01, Vol.9 (9), p.803-819
19.
Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial
by Oneko, Martina
Nature medicine, 2021-09, Vol.27 (9), p.1636-1645
20.
Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study
by McGready, R, Dr
The Lancet infectious diseases, 2012, Vol.12 (5), p.388-396
